Severe bleeding is one of the leading causes of preventable death in trauma situations, but the current system of treatment faces major challenges. The standard method to deliver Tranexamic Acid (TXA), a drug proven to reduce blood loss and improve survival, is through intravenous (IV) administration. While effective, IV access requires trained medical personnel and can be very difficult to establish in chaotic, high-stress environments such as accident scenes, battlefields, or natural disasters. These delays are dangerous — research shows that every 15-minute delay in giving TXA reduces its effectiveness by 10%.
A new study has introduced a potential solution: an autoinjector that delivers TXA as effectively as IV methods but in less than five minutes and without the need for medical expertise. Conducted by researchers at the Hebrew University of Jerusalem in partnership with the IDF Medical Corps, the study demonstrated that the autoinjector achieves rapid therapeutic levels and maintains stable conditions comparable to IV delivery.
This innovation addresses a critical gap in trauma care. Because the device is portable and simple to use, even non-medical responders can administer lifesaving treatment almost instantly. According to Prof. Arik Eisenkraft, “when someone is bleeding heavily, every minute matters.” The autoinjector ensures that patients receive care in the crucial early moments after injury, when survival odds are most at risk.
By eliminating the barriers of time, expertise, and equipment, this breakthrough could transform emergency medicine. From combat zones to roadside accidents, the TXA autoinjector offers a fast, accessible, and effective tool that has the potential to save countless lives worldwide.
Artículo escrito por Danae Marx
14/09/2025
Source:
Eureka alert